Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 12, 2016Current Opinion in RheumatologyOpen Access

Targeting the interleukin-23/17 axis in axial spondyloarthritis

View Full Paper
Ask AI
Bookmark
Share

Authors

APAnanta PaineUniversity of Rochester Medical CenterCRChristopher T. RitchlinUniversity of Rochester Medical Center

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Paine et al. (2016) studied this question.

synapsesocial.com/papers/6aa2f48f2e133cb72ffdd080https://doi.org/10.1097/bor.0000000000000301
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice2014 · 42 citations
  2. 2Interleukin‐17–positive mast cells contribute to synovial inflammation in spondylarthritis2011 · 269 citations
  3. 3Brief Report: Enrichment of Activated Group 3 Innate Lymphoid Cells in Psoriatic Arthritis Synovial Fluid2015 · 114 citations
  4. 4Enrichment of circulating interleukin‐17–secreting interleukin‐23 receptor–positive γ/δ T cells in patients with active ankylosing spondylitis2011 · 262 citations